This genotype subgroup of Ideal was when compared to overall study cohorts. Comparisons weren’t prospectively defined during the randomized trials. There is absolutely no adjustment for differences in baseline features of the trial populations. The beta1-adrenergic receptor 389 Arginine/Glycine polymorphism may be influenced by racial variations that vary in European versus American populations, and various other adrenergic receptor polymorphisms that could impact beta-blocker response also exhibit racial variations in allele frequencies.The announcement was made yesterday during a presentation by AMRI’s Dr. Peter Guzzo, director, discovery development and research, at the 6th Weight problems and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported. The multiple ascending dosage study will be executed in overweight subjects to evaluate pharmacodynamics , including caloric intake, food cravings assessments and metabolic markers.